drugset / Trial / NCT05769153
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Timeline
- Start
- 2023-12-06
- Primary completion
- 2027-05
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR-14034 | Unknown | — | Intravitreal |
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |